Apollon Formularies (AQSE:APOL) | RNS | Apollon Formularies - Combined Formulations Kill Breast Cancer Cells
Breast Cancer Cells Through Multiple Pathways LONDON/TORONTO, Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION, "Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cel...
Source: proactiveinvestors.co.uk